The global cholesterol and lipid test market size reached USD 2.7 billion in 2023 and is anticipated to expand at a 7.6% CAGR during the forecast period. Total market valuation is predicted to increase from USD 3.0 billion in 2024 to USD 6.2 billion by 2034.
| Attributes | Key Insights |
|---|---|
| Cholesterol and Lipid Test Market Value in 2023 | USD 2.7 billion |
| Estimated Cholesterol and Lipid Test Market Value (2024E) | USD 3.0 billion |
| Projected Cholesterol and Lipid Test Market Value (2034F) | USD 6.2 billion |
| Expected Cholesterol and Lipid Test Market CAGR of (2024 to 2034) | 7.6% |
| Market Share of Top 5 Countries | 51.9% |
Cholesterol and Lipid Test Market Overview
Cholesterol and lipid tests are becoming ideal means of monitoring and maintaining cholesterol levels in the body. These tests are set to help detect bad cholesterol or low-density lipoprotein (LDL) and different cardiovascular diseases.
High cholesterol levels often lead to atherosclerosis, narrowing the arteries and making it more difficult for blood to flow through the vessels. This can result in the development of cardiovascular illnesses. The rising need for atherosclerosis screening for early detection and treatment is expected to fuel sales of cholesterol and lipid test solutions.
A routine blood cholesterol test should be performed to ascertain the level of cholesterol accumulation. The recommended total cholesterol level is 200mg/dL or below (ATP III), according to the National Cholesterol Education Programme (NCEP) Third Adult Treatment Panel.
The NCEP suggests that triglyceride levels be less than 150 mg/dL, HDL levels above or equal to 40 mg/dL, and LDL levels less than 100 mg/dL. For this purpose, cholesterol and lipid tests are widely used.
Other factors influencing market growth include:
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The cholesterol and lipid test market expanded historically at a CAGR of 7.6% between 2019 and 2023. It attained a value of around USD 2.7 billion at the end of 2023.
In 2022, the cholesterol and lipid test market accounted for around 9.6% of the global rapid test market, valued at USD 28.5 billion. Over the forecast period, the global market for cholesterol and lipid tests is anticipated to expand at a CAGR of 7.6%.
| Historical CAGR (2019 to 2023) | 7.6% |
|---|---|
| Forecast CAGR (2024 to 2034) | 7.6% |
Cholesterol and lipid testing have been critical to cardiovascular disease management for several decades. The development of cholesterol testing began in the mid-20th century with the introduction of tests for total cholesterol levels.
The market for cholesterol and lipids tests is anticipated to expand as a result of the rising demand for over-the-counter cholesterol and lipids test kits and expanding electronic miniaturization. Subsequently, the rising popularity of preventive healthcare, the development of self-testing kits, and raising awareness about the importance of cholesterol level assessment will boost the market.
The aging population and the widespread adoption of the Western lifestyle in developing nations result in higher levels of atherogenic dyslipidemia and cholesterol. This is expected to fuel sales of cholesterol and lipid test products.
Cardiovascular diseases, including heart disease and strokes, remain a leading cause of mortality worldwide. The rising prevalence of these conditions and the growing awareness of the importance of cholesterol and lipid management are expected to drive the demand for cholesterol and lipids tests.
There is also a shift toward proactive healthcare and preventive measures to mitigate the risk of cardiovascular diseases. Cholesterol and lipid tests are crucial for identifying individuals at risk and guiding preventive strategies. The emphasis on preventive care is expected to fuel cholesterol and lipid test industry demand.
Demand for early diagnosis and treatment is anticipated to increase rapidly. This is due to the increasing prevalence of cardiovascular illnesses and their risk factors, including diabetes and hypertension.
Regular cholesterol and lipids testing is necessary for patients with a history of heart attacks to assess how well their therapy is working. As a result, the cholesterol and lipid test market is anticipated to expand steadily throughout the forecast period due to the increasing incidence of cardiac illnesses.
There is a growing emphasis on preventive healthcare to address the burden of cardiovascular diseases. Cholesterol and lipids tests are essential for early detection, risk assessment, and monitoring of lipid profiles. The increasing adoption of preventive healthcare strategies opens up opportunities for the market.
Long-term difficulties with cost, misinterpretation of the electronic result, and fasting before cholesterol testing could significantly limit the use of cholesterol and lipid tests during the forecast period. Similarly, the lack of LDL and HDL testing characteristics will restrain market growth.
Understanding the results of a handful of at-home cholesterol test kits can be challenging since they are tough to use. End-users might not get an accurate result if the tool is not used properly. It could be more expensive to get electronic testing kits or cholesterol test kits that check triglycerides, LDL, and HDL levels.
Certain cholesterol and lipid tests require end-users to send a blood sample to the laboratory for analysis. This can cost money and put users through weeks of waiting for results.
The table below shows the anticipated growth rates of the top countries. India, Germany, and the United Kingdom are expected to record lucrative CAGRs of 8.4%, 7.6%, and 7.8%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 6.4% |
| China | 6.8% |
| United Kingdom | 7.8% |
| Japan | 6.5% |
| Germany | 7.6% |
| India | 8.4% |
The United States held a significant revenue share of about 90.6% of the North America cholesterol and lipid test market in 2023. The total cholesterol and lipid test market value in the United States reached USD 787.02 million at the end of 2023.
As per the latest report, demand for cholesterol and lipid tests in the United States is projected to rise at a 6.4% CAGR through 2034. This is attributable to the rising rates of obesity and heart disease in the United States and the increasing need for preventive healthcare.
There has been a sharp rise in the cases of obesity and other cardiovascular diseases in the United States during the last several years. For instance, as per the 2017 to 2018 National Health and Nutrition Examination Survey (NHANES), around 42% of the United States-based adults aged 20 and over had obesity.
Obesity and other cardiovascular diseases are often linked to high cholesterol levels. As a result, demand for cholesterol and lipid tests is expected to rise rapidly in the country. This is because these tests can help in the early detection and monitoring of CVD risk by providing accurate cholesterol level assessment.
The United States government and several organizations are increasing their efforts to raise public awareness about cardiovascular diseases, including their diagnosis and treatments. This will likely improve the United States cholesterol and lipid test market share through 2034.
Germany’s cholesterol and lipid test market value totaled USD 157.10 million in 2023. Over the forecast period, demand for cholesterol and lipid test products in Germany is predicted to rise at a 7.6% CAGR.
Multiple factors are expected to drive cholesterol and lipid test demand in Germany. These include increasing cases of cardiovascular diseases, rising need for lipoprotein measurement to detect the risk of cardiovascular diseases, and rising support from the government and other organizations.
The National Nutrition Society is a key player in Germany's effort to create clinical standards for treating cardiovascular disease. It has created new health promotion initiatives, especially in light of the nation’s growth in diabetes and obesity.
The new promotional strategies and policies will likely boost the adoption rate of cholesterol and lipid testing devices in the country. This will foster the growth of the cholesterol and lipid test market in Germany.
China dominated the East Asia cholesterol and lipid test market in 2023 with a share of about 45.3%. Total cholesterol and lipid test revenue in China reached USD 194.01 million at the end of 2023.
Over the forecast period, China’s cholesterol and lipid test industry size is projected to expand at a 6.8% CAGR. This is attributable to rising obesity rates across the country, advancements in cholesterol testing technologies, and the portability of electronics and their usefulness in the creation of self-testing kits.
Thanks to advancements in testing technologies, China-based companies are developing more convenient and accurate cholesterol and lipid testing methods. These include home testing kits, pint-of-care testing devices, and other advanced laboratory-based tests. This is expected to improve China's cholesterol and lipid test market share.
The United Kingdom’s cholesterol and lipid test market size reached USD 137.09 million in 2023. For the projection period, a CAGR of 7.8% has been predicted for the United Kingdom’s cholesterol and lipid test industry.
Several factors are expected to boost the growth of the cholesterol and lipid test market in the United Kingdom. These include rising incidence of cholesterol and lipid disorder and rising awareness about the benefits of cholesterol & lipid management.
People across the United Kingdom are becoming aware of the importance of cholesterol and lipid management for preventing cardiovascular disorders. As a result, they are opting for different cholesterol and lipid tests, thereby fostering market growth.
India is emerging as a highly lucrative market for cholesterol and lipid testing products across South Asia. This is due to the rising incidence of cardiovascular disease, increasing government initiatives, and expanding healthcare infrastructure.
The cholesterol and lipid test market value in India totaled USD 79.74 million in 2023. Over the forecast period, demand for cholesterol and lipid tests in India is anticipated to rise at an 8.4% CAGR.
Growing demand for liquid profile diagnostics is another key factor expected to fuel sales of cholesterol and lipid test products. Subsequently, increasing emphasis on blood lipid analysis to determine the risk of developing cardiovascular disease will foster growth.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The section below shows the analyzer kits leading the cholesterol and lipid test market. It is poised to exhibit a CAGR of 7.4% during the forecast period. By test type, the total cholesterol test asthma segment is anticipated to thrive at 6.0% CAGR.
Based on application, the hyperlipidemia segment is expected to dominate the global cholesterol and lipid test industry. It will likely expand at 6.9% CAGR between 2024 and 2034. By end-user, the hospital segment is projected to register a CAGR of 7.5% through 2034.
Market Growth Outlook by Product
| Product | Value CAGR |
|---|---|
| Test Strip Kits | 8.3% |
| Analyzer Kits | 7.4% |
Based on product, the analyzer kits segment generated a revenue of USD 1.9 billion in 2023. Over the assessment period, demand for analyzer kits is projected to rise at a CAGR of 7.4%. This is due to the rising usage of analyzer kits in a variety of settings, including hospitals, clinics, and diagnostic centers.
Advancements in analyzer kits will also drive growth of the target segment. Patients now have better access to cholesterol testing due to the development of cutting-edge testing kits.
Market Growth Outlook by Test Type
| Test Type | Value CAGR |
|---|---|
| Total Cholesterol Test | 6.0% |
| HDL Cholesterol Test | 7.1% |
| LDL Cholesterol Test | 7.9% |
| Triglycerides/VLDL Cholesterol Test | 8.7% |
| Others | 9.0% |
By test type, the total cholesterol test segment attained a valuation of USD 704.0 million in 2023. Over the forecast period, the target segment is anticipated to thrive at a healthy CAGR of 6.0%. It will likely retain its dominance throughout the assessment period.
Demand for total cholesterol tests is anticipated to increase due to the rising prevalence of cardiovascular illnesses and related risk factors, including diabetes and hypertension. Similarly, increasing the prevalence of high cholesterol and other related diseases will also boost the target segment.
Regular cholesterol testing is necessary for patients with a history of heart attacks to assess the efficacy of their medication. As a result, demand for total cholesterol tests is anticipated to rise significantly throughout the forecast period due to the rising prevalence of cardiac disorders.
Market Growth Outlook by Application
| Application | Value CAGR |
|---|---|
| Hyperlipidemia | 6.9% |
| Hypertriglyceridemia | 8.0% |
| Hyperlipoproteinemia | 8.5% |
| Tangier Disease | 6.4% |
| Familial Hypercholesterolemia | 7.5% |
| Others | 8.8% |
Based on application, the hyperlipidemia segment dominated the global cholesterol and lipid test market, holding a value share of about 25.9% in 2023. It will likely expand at a 6.9% CAGR through 2034. This is attributable to the rising prevalence of hyperlipidemia globally.
Poor dietary habits, characterized by high intake of saturated fats, trans fats, and cholesterol-rich foods, contribute to the development of hyperlipidemia. The rising incidence of this medical condition is expected to create demand for cholesterol and lipid tests.
Consuming foods such as red meat, full-fat dairy products, fried foods, and processed snacks can elevate cholesterol levels, especially low-density lipoprotein (LDL) cholesterol, commonly referred to as "bad" cholesterol. This will foster the growth of the target segment.
Market Growth Outlook by End-user
| End-user | Value CAGR |
|---|---|
| Clinics | 6.8% |
| Hospitals | 7.5% |
| Ambulatory Surgical Centers | 8.3% |
| Homecare Settings | 7.8% |
| Diagnostic Centers | 7.2% |
By end-users, the adoption of cholesterol and lipid test products remains high in hospitals. The target segment generated a revenue of about USD 765.5 million in 2023, holding 28.1% of the total market share.
For the assessment period, the hospitals segment is poised to exhibit a CAGR of 7.5%. This is due to the rising preference of people towards opting for cholesterol and lipid tests in hospitals due to lower costs.
Patients’ preference over choosing hospitals also includes factors such as disease severity, medical personnel availability, and availability of advanced machinery & better healthcare facilities. Hence, the hospital segment will continue to dominate the target market through 2034.
In recent years, leading players have introduced new technologies and products in the cholesterol and lipid test market. For example, Boditech Med introduced Ichorma LDL Cholesterol Direct in October 2021, and Ichroma AST secured export licenses. Both serve as warning signs for preventing lifestyle disorders, including arteriosclerosis, hypertension, diabetes, stroke, liver disease, etc.
Recent Developments in the Cholesterol and Lipid Test Market
The global cholesterol and lipid test market value totaled USD 2.7 billion in 2023.
Demand for cholesterol and lipid tests is expected to expand at a 7.6% CAGR.
By 2034, the market size is set to reach USD 6.2 billion.
Abbott Laboratories, AstraZeneca, LivaNova, and Boston Scientific Corporation.
Germany, the United States, China, Japan, and the United Kingdom.
North America held a market share of 31.9% in 2023.
Technology advancement in tests and rising prevalence of obesity.
Demand in Europe is expected to rise at 8.4% CAGR through 2034.
It costs around 320 to 250 rupees in India.
A blood test is used to measure levels of cholesterol and other fats in blood.
Cholesterol lipid profile test price varies from 340 to 1000 in India.
| CAGR | 7.3% |
|---|---|
| Market Size - 2023 | USD 2660.3 million |
| Market Size - 2033 | USD 5,379.2 million |
| Current Year Value (2023) | USD 280.6 million |
|---|---|
| Expected Forecast Value (2033) | USD 445.3 million |
| Projected CAGR (2023 to 2033) | 4.7% |
| Market Estimated Size (2022) | USD 568.1 Million |
|---|---|
| Market Size Projected (2029) | USD 786.2 Million |
| Market Value-based CAGR (2022 to 2029) | 4.8% |
| Market Value 2022 | USD 440.6 Million |
|---|---|
| Market Value 2028 | USD 514.7 Billion |
| CAGR 2022 to 2028 | 2.6% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Cholesterol and Lipid Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
